Advanced Search

9D10 (ATCC® CRL-8752™)

Organism: Homo sapiens, human  /  Cell Type:: B lymphocyte; Epstein-Barr virus (EBV) transforme  /  Tissue: spleen  / 

Permits and Restrictions

View Permits

Organism Homo sapiens, human
Tissue spleen
Cell Type B lymphocyte; Epstein-Barr virus (EBV) transforme
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 2 Cells Contain HERPESVIRUS

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Applications
The antibody is specific for the lipopolysaccharide of the Fisher immunotype 4 of P. aeruginosa.
Storage Conditions liquid nitrogen vapor phase
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC.
Genes Expressed
immunoglobulin; monoclonal antibody; against Pseudomonas aeruginosa lipopolysaccharide (LPS) of Fisher immunotype 4 (IATS type 1)
Cellular Products
immunoglobulin; monoclonal antibody; against Pseudomonas aeruginosa lipopolysaccharide (LPS) of Fisher immunotype 4 (IATS type 1)
Comments
B cells from peripheral blood of an individual known to have been exposed to P. aeruginosa were transformed with Epstein-Barr virus (EBV).
The antibody is specific for the lipopolysaccharide of the Fisher immunotype 4 of P. aeruginosa.
Complete Growth Medium The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 20%.
The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 20%.
Subculturing
Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 X 10(5) cells/ml. Do not allow the cell concentration to reach 2 X 10(6) cells/ml.
Interval: Maintain cell density between 2 X 10(5) and 1 X 10(6) viable cells/ml.
Medium Renewal: Every 2 to 3 days
Cryopreservation
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Culture Conditions
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
STR Profile
Amelogenin: X,Y
CSF1PO: 10,12
D13S317: 9,13
D16S539: 11,13
D5S818: 11,12
D7S820: 8,11
THO1: 6,7
TPOX: 8
vWA: 14,17
Isotype IgM
Population Doubling Time 24 to 36 hrs
Name of Depositor Miles Inc., Genetics Systems Corporation
U.S. Patent Number
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC.
References

Siadak AW, Lostrom ME. Human monoclonal antibodies to serotypic lipopolysaccharide determinants on Gram-negative bacteria and their production. US Patent 4,834,975 dated May 30 1989

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Product Sheet
Product Sheet
Certificate of Analysis
Certificate of Analysis
SDS
SDS
References

Siadak AW, Lostrom ME. Human monoclonal antibodies to serotypic lipopolysaccharide determinants on Gram-negative bacteria and their production. US Patent 4,834,975 dated May 30 1989